The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. securities between October 31, ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

It is with great sadness that the Boards of Trustees of Richards Packaging Income Fund (the "Fund") announce today the passing of Gerry Glynn, Trustee. Gerry passed peacefully in his sleep after a ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

In the last week, the United States market has stayed flat, but it is up 7.8% over the past year with earnings forecast to grow by 14% annually. In this context of steady growth and positive ...

In the last week, the United States market has stayed flat, yet it is up 7.8% over the past year with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends in the pharmaceutical sector.